Clinical Trials Browser

Phase 3 × sacituzumab govitecan × Breast × Clear all

Triple Negative Breast Neoplasms

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Phase 3 Recruiting

364 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05382299 2026-04-06

ASCENT-03

Phase 3 Active not recruiting

623 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Phase 3 Not yet recruiting

376 enrolled

Breast

Breast Neoplasms

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Phase 3 Active not recruiting

331 enrolled

Breast

Breast Neoplasms

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

1,514 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05840211 2025-10-03

ASCENT-07

Phase 3 Active not recruiting

654 enrolled

Breast

Breast Neoplasms

NCT05382286 2025-09-18

ASCENT-04

Phase 3 Active not recruiting

443 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07178730 2025-09-17

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

Phase 3 Recruiting

96 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

543 enrolled 25 charts 2 FDA

Breast

Breast Neoplasms

NCT02574455 2022-06-15

ASCENT

Phase 3 Completed

529 enrolled 23 charts 2 FDA

Breast

Breast Neoplasms

Clinical Trials

SASCIA

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

ASCENT-03

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

ADAPT-TN-III

ASCENT-07

ASCENT-04

ADAPT-TN-IV

ISIdE

TROPiCS-02

ASCENT